O	0	3	The
O	4	11	Effects
O	12	14	of
O	15	16	a
B-intervention	17	23	Remote
I-intervention	23	24	-
I-intervention	24	29	based
I-intervention	30	36	Weight
I-intervention	37	41	Loss
I-intervention	42	49	Program
O	50	52	on
O	53	67	Adipocytokines
O	67	68	,
O	69	78	Metabolic
O	79	86	Markers
O	86	87	,
O	88	91	and
O	92	100	Telomere
O	101	107	Length
O	108	110	in
O	111	117	Breast
O	118	124	Cancer
O	125	134	Survivors
O	134	135	:
O	136	139	the
O	140	145	POWER
O	145	146	-
O	146	152	Remote
O	153	158	Trial
O	158	159	.

O	160	162	We
O	163	172	initiated
O	173	174	a
O	175	183	clinical
O	184	189	trial
O	190	192	to
O	193	202	determine
O	203	206	the
O	207	217	proportion
O	218	220	of
O	221	227	breast
O	228	234	cancer
O	235	244	survivors
O	245	254	achieving
O	255	256	≥
O	256	257	5
O	257	258	%
O	259	265	weight
O	266	270	loss
O	271	276	using
O	277	278	a
O	279	287	remotely
O	288	297	delivered
O	298	304	weight
O	305	309	loss
O	310	322	intervention
O	323	324	(
O	324	329	POWER
O	329	330	-
O	330	336	remote
O	336	337	)
O	338	340	or
O	341	342	a
O	343	347	self
O	347	348	-
O	348	356	directed
O	357	365	approach
O	365	366	,
O	367	370	and
O	371	373	to
O	374	383	determine
O	384	387	the
O	388	395	effects
O	396	398	of
O	399	402	the
O	403	415	intervention
O	416	418	on
O	419	429	biomarkers
O	430	432	of
O	433	439	cancer
O	440	444	risk
O	445	454	including
O	455	465	metabolism
O	465	466	,
O	467	479	inflammation
O	479	480	,
O	481	484	and
O	485	493	telomere
O	494	500	length
O	500	501	.

B-eligibility	502	507	Women
I-eligibility	508	512	with
I-eligibility	513	518	stage
I-eligibility	519	520	0
I-eligibility	520	521	-
I-eligibility	521	524	III
I-eligibility	525	531	breast
I-eligibility	532	538	cancer
I-eligibility	538	539	,
I-eligibility	540	543	who
I-eligibility	544	553	completed
I-eligibility	554	559	local
I-eligibility	560	567	therapy
I-eligibility	568	571	and
I-eligibility	572	584	chemotherapy
I-eligibility	584	585	,
I-eligibility	586	590	with
I-eligibility	591	592	a
I-eligibility	593	597	body
I-eligibility	598	602	mass
I-eligibility	603	608	index
I-eligibility	609	610	≥
I-eligibility	610	612	25
I-eligibility	613	615	kg
I-eligibility	615	616	/
I-eligibility	616	618	m2
O	619	623	were
O	624	634	randomized
O	635	637	to
O	638	639	a
O	640	642	12
O	642	643	-
O	643	648	month
O	649	661	intervention
O	662	663	(
O	663	668	POWER
O	668	669	-
O	669	675	remote
O	675	676	)
O	677	683	versus
O	684	685	a
B-control	686	690	self
I-control	690	691	-
I-control	691	699	directed
I-control	700	708	approach
O	708	709	.

O	710	713	The
O	714	721	primary
O	722	731	objective
O	732	735	was
O	736	738	to
O	739	748	determine
O	749	752	the
B-outcome-Measure	753	759	number
I-outcome-Measure	760	762	of
I-outcome-Measure	763	768	women
I-outcome-Measure	769	772	who
I-outcome-Measure	773	781	achieved
I-outcome-Measure	782	784	at
I-outcome-Measure	785	790	least
I-outcome-Measure	791	792	5
I-outcome-Measure	792	793	%
I-outcome-Measure	794	800	weight
I-outcome-Measure	801	805	loss
I-outcome-Measure	806	808	at
I-outcome-Measure	809	810	6
I-outcome-Measure	811	817	months
O	817	818	.

O	819	821	We
O	822	830	assessed
O	831	839	baseline
O	840	843	and
O	844	845	6
O	845	846	-
O	846	851	month
O	852	858	change
O	859	861	in
O	862	863	a
O	864	869	panel
O	870	872	of
O	873	887	adipocytokines
O	888	889	(
O	889	900	adiponectin
O	900	901	,
O	902	908	leptin
O	908	909	,
O	910	918	resistin
O	918	919	,
O	920	923	HGF
O	923	924	,
O	925	928	NGF
O	928	929	,
O	930	934	PAI1
O	934	935	,
O	936	939	TNF
O	939	940	α
O	940	941	,
O	942	946	MCP1
O	946	947	,
O	948	951	IL1
O	951	952	β
O	952	953	,
O	954	957	IL6
O	957	958	,
O	959	962	and
O	963	966	IL8
O	966	967	)
O	967	968	,
O	969	978	metabolic
O	979	986	factors
O	987	988	(
O	988	995	insulin
O	995	996	,
O	997	1004	glucose
O	1004	1005	,
O	1006	1012	lipids
O	1012	1013	,
O	1014	1016	hs
O	1016	1017	-
O	1017	1020	CRP
O	1020	1021	)
O	1021	1022	,
O	1023	1026	and
O	1027	1035	telomere
O	1036	1042	length
O	1043	1045	in
O	1046	1056	peripheral
O	1057	1062	blood
O	1063	1074	mononuclear
O	1075	1080	cells
O	1080	1081	.

O	1082	1086	From
O	1087	1091	2013
O	1092	1094	to
O	1095	1099	2015
O	1099	1100	,
B-total-participants	1101	1103	96
O	1104	1109	women
O	1110	1114	were
O	1115	1123	enrolled
O	1123	1124	,
O	1125	1128	and
B-total-participants	1129	1131	87
O	1132	1136	were
O	1137	1146	evaluable
O	1147	1150	for
O	1151	1154	the
O	1155	1162	primary
O	1163	1171	analysis
O	1171	1172	;
B-intervention-participants	1173	1175	45
O	1176	1178	to
O	1179	1184	POWER
O	1184	1185	-
O	1185	1191	remote
O	1192	1195	and
B-control-participants	1196	1198	42
O	1199	1201	to
O	1202	1206	self
O	1206	1207	-
O	1207	1215	directed
O	1215	1216	.

B-outcome	1217	1219	At
I-outcome	1220	1221	6
I-outcome	1222	1228	months
O	1228	1229	,
B-iv-bin-percent	1230	1232	51
I-iv-bin-percent	1232	1233	%
O	1234	1236	of
O	1237	1242	women
O	1243	1253	randomized
O	1254	1256	to
O	1257	1262	POWER
O	1262	1263	-
O	1263	1269	remote
B-outcome	1270	1274	lost
I-outcome	1275	1276	≥
I-outcome	1276	1277	5
I-outcome	1277	1278	%
I-outcome	1279	1281	of
I-outcome	1282	1287	their
I-outcome	1288	1296	baseline
I-outcome	1297	1301	body
I-outcome	1302	1308	weight
O	1308	1309	,
O	1310	1318	compared
O	1319	1323	with
B-cv-bin-percent	1324	1326	12
I-cv-bin-percent	1326	1327	%
O	1328	1330	in
O	1331	1334	the
O	1335	1339	self
O	1339	1340	-
O	1340	1348	directed
O	1349	1352	arm
O	1353	1354	[
O	1354	1356	OR
O	1356	1357	,
O	1358	1359	7
O	1359	1360	.
O	1360	1361	9
O	1361	1362	;
O	1363	1365	95
O	1365	1366	%
O	1367	1377	confidence
O	1378	1386	interval
O	1387	1388	(
O	1388	1390	CI
O	1390	1391	)
O	1391	1392	,
O	1393	1394	2
O	1394	1395	.
O	1395	1396	6
O	1396	1397	-
O	1397	1399	23
O	1399	1400	.
O	1400	1401	9
O	1401	1402	;
O	1403	1404	P
O	1405	1406	=
O	1407	1408	0
O	1408	1409	.
O	1409	1413	0003
O	1413	1414	]
O	1414	1415	;
O	1416	1426	proportion
O	1427	1431	were
O	1432	1439	similar
B-outcome	1440	1442	at
I-outcome	1443	1445	12
I-outcome	1446	1452	months
O	1453	1454	(
B-iv-bin-percent	1454	1456	51
I-iv-bin-percent	1456	1457	%
O	1458	1460	vs
B-cv-bin-percent	1461	1463	17
I-cv-bin-percent	1463	1464	%
O	1464	1465	,
O	1466	1478	respectively
O	1478	1479	,
O	1480	1481	P
O	1482	1483	=
O	1484	1485	0
O	1485	1486	.
O	1486	1489	003
O	1489	1490	)
O	1490	1491	.

O	1492	1498	Weight
O	1499	1503	loss
O	1504	1514	correlated
O	1515	1519	with
O	1520	1531	significant
O	1532	1541	decreases
O	1542	1544	in
O	1545	1551	leptin
O	1551	1552	,
O	1553	1556	and
O	1557	1566	favorable
O	1567	1577	modulation
O	1578	1580	of
O	1581	1593	inflammatory
O	1594	1603	cytokines
O	1604	1607	and
O	1608	1613	lipid
O	1614	1622	profiles
O	1622	1623	.

O	1624	1629	There
O	1630	1633	was
O	1634	1636	no
O	1637	1648	significant
O	1649	1655	change
O	1656	1658	in
O	1659	1667	telomere
O	1668	1674	length
O	1675	1677	at
O	1678	1679	6
O	1680	1686	months
O	1686	1687	.

O	1688	1689	A
O	1690	1698	remotely
O	1699	1708	delivered
O	1709	1715	weight
O	1716	1720	loss
O	1721	1733	intervention
O	1734	1742	resulted
O	1743	1745	in
O	1746	1757	significant
O	1758	1764	weight
O	1765	1769	loss
O	1770	1772	in
O	1773	1779	breast
O	1780	1786	cancer
O	1787	1796	survivors
O	1796	1797	,
O	1798	1801	and
O	1802	1811	favorable
O	1812	1819	effects
O	1820	1822	on
O	1823	1830	several
O	1831	1841	biomarkers
O	1841	1842	.
